Evidence map›Paper›PMID 26347184›Full record

Trial reportJournal of neural transmission (Vienna, Austria : 1996)2015

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.

Mikko Kuoppamäki, Mika Leinonen, Werner Poewe

2 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase IIIComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of neural transmission (Vienna, Austria : 1996), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06115538 phase4unknown statusnot on this mapstarted 2023, after this paper: background citation

Comparison of Blood Dopamine Levels in Idiopathic Parkinson's Patients Receiving Levodopa Carbidopa Entacapone or Levodopa Benserazide

TypeinterventionalSponsorAnkara Ataturk Sanatorium Training and Research HospitalRan2023 to 2025Enrolled96ConditionsParkinson Disease, Treatment AdherenceArmsLevodopa
NCT06928519 recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study

TypeobservationalSponsorYousheng XiaoRan2025 to 2027Enrolled216ConditionsParkinson Disease (PD)
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Mikko KuoppamäkiOrion Pharma/R&D, P.O. Box 425, 20101, Turku, Finland. mikko.kuoppamaki@orionpharma.com.
Mika Leinonen4Pharma AB, Stockholm, Sweden.
Werner PoeweUniversitätsklinik für Neurologie, Leopold-Franzens-Universität, Innsbruck, Austria.
PledPharma (Sweden) · SEUniversität Innsbruck · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Entacapone is frequently used together with levodopa/carbidopa (LC) and levodopa/benserazide (LB) in the treatment of Parkinson's disease (PD) patients with wearing-off symptoms. It is generally assumed that the effects of entacapone are independent of the type of decarboxylase inhibitor used, but there is very little published data available on the efficacy of entacapone administered with LB versus LC. We have performed a pooled analysis of three randomized, double-blind, 6-month, phase III studies to compare the treatment effects of entacapone (compared to placebo) in PD patients receiving LC or LB. A total of 551 PD patients experiencing wearing-off were included in the analysis. 300 patients were on LB and 251 on LC at baseline. At 6 months, entacapone (compared to placebo) improved mean daily OFF-time in patients on LB and LC by 0.76 (p = 0.016) and 0.95 (p = 0.011) hours, respectively. The corresponding improvements in ON-time were 0.97 (p = 0.002) and 0.83 h (p = 0.022), respectively. The treatment effects of entacapone both in LB and LC users were statistically significant (p < 0.05) also in UPDRS II and III scores, except in UPDRS II scores in patients receiving LC (p = 0.20). None of the treatment effects of entacapone were statistically significantly different between patients receiving LB or LC. Reported adverse events were comparable between LB and LC users. We conclude that entacapone provided comparable benefits in PD patients with wearing-off symptoms using either LB or LC.

Indexed as

Antiparkinson AgentsBenserazideCarbidopaCatechol O-Methyltransferase InhibitorsCatecholsData Interpretation, StatisticalDouble-Blind MethodDrug CombinationsDrug Therapy, CombinationFemaleHumansLevodopaMaleMiddle AgedNitrilesParkinson DiseaseAntiparkinson AgentsBenserazidebenserazide, levodopa drug combinationCarbidopacarbidopa, levodopa drug combinationCatechol O-Methyltransferase InhibitorsCatecholsDrug CombinationsentacaponeLevodopaNitrilesBenserazideCarbidopaEntacaponeLevodopaParkinson’s disease

Identifiers

PMID26347184
PMCPMC4644189
OpenAlexW1598813848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.